JP2007502602A5 - - Google Patents

Download PDF

Info

Publication number
JP2007502602A5
JP2007502602A5 JP2006523492A JP2006523492A JP2007502602A5 JP 2007502602 A5 JP2007502602 A5 JP 2007502602A5 JP 2006523492 A JP2006523492 A JP 2006523492A JP 2006523492 A JP2006523492 A JP 2006523492A JP 2007502602 A5 JP2007502602 A5 JP 2007502602A5
Authority
JP
Japan
Prior art keywords
prostate
composition
vaccine construct
subject
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006523492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007502602A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2004/001129 external-priority patent/WO2005019464A1/en
Publication of JP2007502602A publication Critical patent/JP2007502602A/ja
Publication of JP2007502602A5 publication Critical patent/JP2007502602A5/ja
Pending legal-status Critical Current

Links

JP2006523492A 2003-08-21 2004-08-20 前立腺癌の治療用の前立腺特異的抗原をコードするポックスウィルスベクター Pending JP2007502602A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003904496A AU2003904496A0 (en) 2003-08-21 A novel vector
PCT/AU2004/001129 WO2005019464A1 (en) 2003-08-21 2004-08-20 Poxvirus vector encoding prostate specific antigens for treatment of prostate cancer

Publications (2)

Publication Number Publication Date
JP2007502602A JP2007502602A (ja) 2007-02-15
JP2007502602A5 true JP2007502602A5 (cg-RX-API-DMAC10.html) 2007-12-06

Family

ID=34200696

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006523492A Pending JP2007502602A (ja) 2003-08-21 2004-08-20 前立腺癌の治療用の前立腺特異的抗原をコードするポックスウィルスベクター

Country Status (7)

Country Link
US (1) US20070196346A1 (cg-RX-API-DMAC10.html)
EP (1) EP1660664A4 (cg-RX-API-DMAC10.html)
JP (1) JP2007502602A (cg-RX-API-DMAC10.html)
AU (2) AU2004267117B2 (cg-RX-API-DMAC10.html)
CA (1) CA2536317A1 (cg-RX-API-DMAC10.html)
NZ (1) NZ545438A (cg-RX-API-DMAC10.html)
WO (1) WO2005019464A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2608604T3 (es) * 2007-10-18 2017-04-12 Bavarian Nordic A/S Uso de MVA para tratar el cáncer de próstata
JP6124460B2 (ja) * 2012-02-16 2017-05-10 国立大学法人 岡山大学 融合タンパク質を含む癌治療用医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
EP0954593A1 (en) * 1996-07-25 1999-11-10 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
EP0973916A1 (en) * 1997-04-11 2000-01-26 Dendreon Corporation Composition and method for inducing an immune response against tumour-related antigens
EP1246646A2 (en) * 2000-01-05 2002-10-09 Aventis Pasteur Limited Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen
AU2002239441A1 (en) * 2000-11-01 2002-05-27 American Foundation For Biological Research, Inc. Methods and compositions for inducing cell-mediated immune responses
DE60235041D1 (de) * 2001-11-30 2010-02-25 Us Gov Health & Human Serv Und ihre verwendung
US7179797B2 (en) * 2002-09-27 2007-02-20 Wisconsin Alumni Research Foundation Methods and compositions for treating prostate cancer using DNA vaccines

Similar Documents

Publication Publication Date Title
Cottingham et al. Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA)
ES2647662T3 (es) Vacunas de ADN infeccioso frente al virus chikungunya
US9951352B2 (en) Poxvirus expression system
Carroll et al. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model
JP6153473B2 (ja) B型肝炎ウイルスコアタンパク質をコードする核酸分子およびそれを含むワクチン
CN1266459A (zh) 用于产生cd8t细胞免疫应答的接种方法和试剂
RU2014104360A (ru) Мутантные полимеразы вируса гепатита в
JP2010259446A5 (cg-RX-API-DMAC10.html)
EP2391383B1 (en) Codon-optimized hepatitis b virus core antigen (hbcag)
CN107922981B (zh) 用于增强在痘病毒中的表达的启动子
JP2013014588A (ja) Mvaの使用に基づくワクチン
US20130045234A1 (en) Neutralizing factors as vaccine adjuvants
JP2021506300A (ja) B型肝炎ウイルス(hbv)に対する免疫応答を誘導するための方法および組成物
Jiang et al. Immunization with adenovirus LIGHT-engineered dendritic cells induces potent T cell responses and therapeutic immunity in HBV transgenic mice
US6682742B1 (en) Vector for integration of heterologous sequences into poxviral genomes
CA2909225C (en) Mutant vaccinia virus strains, uses thereof and method of producing the same
CN1653182A (zh) 重组禽痘病毒
CN1723285A (zh) 重组的mva及其产生方法
RU2006145306A (ru) Аденовирусный/альфавитный гибридный вектор для эффективного введения и экспрессии терапевтических генов в опухолевые клетки
CN102000330B (zh) 一种核酸疫苗佐剂及其构建方法
Nemeckova et al. Experimental therapy of HPV16 induced tumors with IL12 expressed by recombinant vaccinia virus in mice
US10160979B2 (en) Pharmaceutical composition for treatment and/or prevention of hepatitis C
CN1357622A (zh) 人白细胞白介素-12重组昆虫病毒株及其制备方法
JPWO2006013815A1 (ja) HCVウイルスタンパク質をコードするDNAを保有する組換えワクチニアウイルスDIs株、およびその利用
Spencer Matthew G. Cottingham, Rikke F. Andersen, Alexandra J. Spencer, Saroj Saurya, Julie Furze, Adrian VS Hill and Sarah C. Gilbert